<DOC>
	<DOCNO>NCT00598806</DOCNO>
	<brief_summary>The primary endpoint evaluate recurrence rate 2 year randomize patient tumor histology Ta , G1-G2 receive TUR-BT plus EOquin® versus receive TUR-BT plus placebo .</brief_summary>
	<brief_title>Phase 3 Trial Single-Dose Intravesical EOquin® Surgical Adjuvant Noninvasive Bladder Cancer</brief_title>
	<detailed_description>This multicenter , randomize , placebo-controlled , double-blind , study . Following TUR-BT , eligible patient randomize receive either intravesical EOquin® ( Apaziquone ) match placebo instill within 6 hour surgery . Patients see postoperative follow-up exam 21±10 day TUR . At time , pathology report review . If histology patient 's tumor Ta , G1-G2 ( low grade [ WHO/ISUP classification ] ) , patient receive treatment observe cystoscopically every three month year two tumor recurrence progression . If histology patient 's tumor Ta , G1-G2 ( low grade [ WHO/ISUP classification ] ) , patient receive treatment accordance current treatment guideline , follow patient follow cystoscopically every three month year two tumor recurrence progression .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Apaziquone</mesh_term>
	<criteria>All following question must answer `` Yes '' order patient participate study . 1 . Has patient give write informed consent ? 2 . Is patient least 18 year old ? 3 . Does patient transitional cell carcinoma bladder clinically apparent tumor Ta , grade G1G2 ? 4 . If patient female childbearing potential , use acceptable/effective method contraception ? 5 . If patient female childbearing potential , negative serum pregnancy test within past 14 day ? 6 . Is patient willing able abide protocol ? All following question must answer `` No '' order patient participate study . 1 . Does patient 5 bladder tumor ? 2 . Does single bladder tumor exceed 3.5 cm diameter ? 3 . Does patient single , primary bladder tumor &lt; 0.5 cm previous diagnosis bladder cancer ? 4 . Has patient ever receive EOquin ( r ) ? 5 . Does patient , patient ever , bladder tumor know tumor Ta grade G1 G2 ( low grade [ WHO/ISUP classification ] ) ? 6 . Does patient , patient ever bladder tumor histology transitional cell carcinoma ? 7 . Does patient , patient ever , CIS ? 8 . Does patient active urinary tract infection ? 9 . Does patient bleed disorder screen platelet count &lt; 100 x 109/L ? 10 . Does patient unstable medical condition would make unsafe him/her undergo TURBT general spinal anesthesia ? 11 . Does patient screen hemoglobin &lt; 10 mg/dL , screen absolute neutrophil count &lt; 1.5 x 109/L ? 12 . Does patient know immunodeficiency disorder ? 13 . Has patient receive investigational treatment within past 30 day ? 14 . Is patient breast feeding ? 15 . Does patient history interstitial cystitis ? 16 . Does patient history allergy red color food dye ? 17 . Has patient transitional cell carcinoma bladder within past 4 month ?</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Noninvasive Bladder Cancer</keyword>
</DOC>